Pleural Fluid Soluble Interleukin-2 Receptor as a Biomarker for the Diagnosis of Tuberculosis Pleural Effusion: A Systematic Review and Meta-Analysis.
Journal
Journal of tropical medicine
ISSN: 1687-9686
Titre abrégé: J Trop Med
Pays: Egypt
ID NLM: 101524194
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
12
2021
revised:
06
02
2022
accepted:
28
02
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
1
4
2022
Statut:
epublish
Résumé
Several studies have assessed the diagnostic accuracy of pleural fluid soluble interleukin-2 receptor (sIL-2R) for tuberculous pleural effusion (TPE) but with varied results. Therefore, we conducted this systematic review and meta-analysis to evaluate the accuracy of sIL-2R for TPE. PubMed, Ovid, and Web of Science databases were searched from inception to 23 March 2021 to identify eligible studies concerning the diagnostic accuracy of fluid sIL-2R for TPE. The sensitivity and specificity of sIL-2R for TPE were pooled with a bivariate model. We estimated the global diagnostic accuracy of PE sIL-2R with a summary receiver operating characteristic (sROC) curve. The revised Quality Assessment for Diagnostic Accuracy Studies tool (QUADAS-2) was used to assess the quality of eligible studies. A total of nine studies with 270 TPEs and 586 non-TPEs were included in the final analysis. The pooled sensitivity and specificity were 0.81 (95% CI: 0.76-0.86) and 0.92 (95% CI: 0.77-0.98), respectively. The area under the sROC curve (AUC) was 0.82 (95% CI: 0.79-0.86). No significant publication bias was observed. Pleural fluid sIL-2R is a useful diagnostic marker for TPE. However, the diagnostic accuracies of already available biomarkers such as pleural fluid adenosine deaminase, interferon-
Sections du résumé
Background
UNASSIGNED
Several studies have assessed the diagnostic accuracy of pleural fluid soluble interleukin-2 receptor (sIL-2R) for tuberculous pleural effusion (TPE) but with varied results. Therefore, we conducted this systematic review and meta-analysis to evaluate the accuracy of sIL-2R for TPE.
Methods
UNASSIGNED
PubMed, Ovid, and Web of Science databases were searched from inception to 23 March 2021 to identify eligible studies concerning the diagnostic accuracy of fluid sIL-2R for TPE. The sensitivity and specificity of sIL-2R for TPE were pooled with a bivariate model. We estimated the global diagnostic accuracy of PE sIL-2R with a summary receiver operating characteristic (sROC) curve. The revised Quality Assessment for Diagnostic Accuracy Studies tool (QUADAS-2) was used to assess the quality of eligible studies.
Results
UNASSIGNED
A total of nine studies with 270 TPEs and 586 non-TPEs were included in the final analysis. The pooled sensitivity and specificity were 0.81 (95% CI: 0.76-0.86) and 0.92 (95% CI: 0.77-0.98), respectively. The area under the sROC curve (AUC) was 0.82 (95% CI: 0.79-0.86). No significant publication bias was observed.
Conclusions
UNASSIGNED
Pleural fluid sIL-2R is a useful diagnostic marker for TPE. However, the diagnostic accuracies of already available biomarkers such as pleural fluid adenosine deaminase, interferon-
Identifiants
pubmed: 35356490
doi: 10.1155/2022/4348063
pmc: PMC8958078
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
4348063Informations de copyright
Copyright © 2022 Zhi Yan et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest regarding the publication of this paper.
Références
Immunol Lett. 2019 Jan;205:9-15
pubmed: 29702147
Arch Bronconeumol. 2014 May;50(5):161-5
pubmed: 24360987
Sci Rep. 2014 Jul 11;4:5658
pubmed: 25014250
Lung. 2015 Aug;193(4):539-48
pubmed: 25944255
Lung. 2001;179(3):175-84
pubmed: 11891607
Adv Exp Med Biol. 2015;852:21-30
pubmed: 25523627
Eur Rev Med Pharmacol Sci. 2015 Oct;19(19):3563-8
pubmed: 26502844
Int J Tuberc Lung Dis. 2000 Oct;4(10):975-9
pubmed: 11055766
Respirology. 2010 Apr;15(3):522-9
pubmed: 20337996
Respiration. 1994;61(3):150-4
pubmed: 8047718
Chest. 2003 Mar;123(3):740-4
pubmed: 12628872
J Clin Epidemiol. 2005 Sep;58(9):882-93
pubmed: 16085191
Cochrane Database Syst Rev. 2018 Aug 27;8:CD012768
pubmed: 30148542
Respirology. 2002 Dec;7(4):311-5
pubmed: 12421238
Chest. 2007 Apr;131(4):1133-41
pubmed: 17426220
Clin Chem. 2012 Sep;58(9):1292-301
pubmed: 22829313
Anticancer Res. 1991 May-Jun;11(3):1365-8
pubmed: 1888173
PLoS One. 2019 Mar 26;14(3):e0213728
pubmed: 30913213
Ann Transl Med. 2020 May;8(9):607
pubmed: 32566633
Med J Armed Forces India. 2011 Oct;67(4):338-42
pubmed: 27365843
Respirology. 2019 Oct;24(10):962-971
pubmed: 31418985
BMJ. 1994 Jun 11;308(6943):1552
pubmed: 8019315
Chest. 1990 May;97(5):1141-3
pubmed: 2331910
Clin Chem. 2012 Nov;58(11):1534-45
pubmed: 22991421
JAMA. 2018 Jan 23;319(4):388-396
pubmed: 29362800
BMC Infect Dis. 2020 Mar 24;20(1):242
pubmed: 32209054
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
J Clin Epidemiol. 2005 Oct;58(10):982-90
pubmed: 16168343
Respiration. 2018;95(6):469-477
pubmed: 29539604
Arch Bronconeumol (Engl Ed). 2019 Jan;55(1):17-22
pubmed: 29801681
Respirology. 2011 Apr;16(3):473-80
pubmed: 21299686
J Interferon Cytokine Res. 2007 May;27(5):353-64
pubmed: 17523867
Ann Intern Med. 1986 Oct;105(4):560-72
pubmed: 3019203
J Immunol. 1985 Nov;135(5):3172-7
pubmed: 3930598
Stat Med. 2002 May 15;21(9):1237-56
pubmed: 12111876
Thorax. 2018 Mar;73(3):240-247
pubmed: 28844060
Arch Intern Med. 1994 May 23;154(10):1097-101
pubmed: 8185423
Infect Dis (Lond). 2015 Mar;47(3):150-5
pubmed: 25549699
BMJ. 2004 Jul 17;329(7458):168-9
pubmed: 15258077
Respiration. 2015;90(3):251-5
pubmed: 26279455
Tuberculosis (Edinb). 2013 May;93(3):279-84
pubmed: 23477939
Respir Med. 2008 May;102(5):744-54
pubmed: 18222681
Chest. 2004 Mar;125(3):987-9
pubmed: 15006958
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120